Media Center

News Releases

KYTHERA Biopharmaceuticals Announces 2015 Outlook Call
March 19, 2015

Westlake Village, Calif., March 19, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it will host a 2015 Outlook investor call and webcast at 4:30 p.m. ET on Thursday, March 26, 2015. Individuals interested in participating in the call should dial (877) 344-3890 (U.S. and Canada) or (760) 666-3770 (international) using conference ID number…

KYTHERA Biopharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters’ Over-Allotment Option
March 16, 2015

Westlake Village, Calif., March 16, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced the closing of its underwritten public offering of 2,994,793 shares of its common stock at a price to the public of $48.00 per share for gross proceeds of approximately $143.8 million, which includes the exercise in full by the underwriters of their…

KYTHERA Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
March 10, 2015

Westlake Village, Calif., March 10, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced the pricing of its underwritten public offering of 2,604,168 shares of its common stock at a price to the public of $48.00 per share, before underwriting discounts and commissions and expenses of the offering, for gross proceeds of approximately $125 million. All…

KYTHERA Biopharmaceuticals Announces Proposed Public Offering of Common Stock
March 9, 2015

Westlake Village, Calif., March 9, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it has commenced an underwritten public offering of $125 million of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by KYTHERA. KYTHERA intends to use the net proceeds…

KYTHERA Biopharmaceuticals Announces FDA Advisory Committee Unanimously (17-0) Recommends to Approve ATX-101 (deoxycholic acid) Injection to Improve the Appearance of Moderate to Severe Submental Fullness
March 9, 2015

Westlake Village, Calif., March 9, 2015 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) announced today that the U.S. Food and Drug Administration’s (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to support the approval of ATX-101 (deoxycholic acid) injection for improvement in the appearance of moderate to severe convexity or fullness associated with submental…

KYTHERA Biopharmaceuticals Announces 2014 Operating Results
March 2, 2015

Westlake Village, Calif., March 2, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its quarter and year ended December 31, 2014, and provided an update on recent accomplishments. “Last year KYTHERA achieved many milestones and this year we continue our upward momentum. Most notably, we filed our New Drug Application for ATX-101…

KYTHERA Acquires Worldwide Rights to Clinical Compound and Key Intellectual Property for Potential Novel Treatment of Hair Loss
February 9, 2015

Westlake Village, Calif., February 10, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that it has entered into separate license agreements with Actelion Pharmaceuticals Ltd. and the University of Pennsylvania for a novel approach for the treatment of hair loss, which together could enable KYTHERA to bring a new treatment to the very large and…

KYTHERA Biopharmaceuticals Submits Drug Application in Australia for Novel Submental Contouring Injectable Drug ATX-101
February 4, 2015

Submission marks company’s fourth ATX-101 global regulatory filing Westlake Village, Calif., February 4, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced its submission to Australia’s Therapeutic Goods Administration (TGA) for ATX-101 (deoxycholic acid), its potential first-in-class treatment for improving submental fullness associated with submental (under the chin) fat. This milestone in KYTHERA’s ATX-101 global…

KYTHERA Biopharmaceuticals To Present at the 2015 Leerink Global Healthcare Conference
February 4, 2015

Westlake Village, Calif., February 4, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference. Event:        2015 Leerink Global Healthcare Conference Date:         Wednesday, February 11, 2015 Time:        10:40 a.m. ET A live webcast will be…

KYTHERA Biopharmaceuticals Announces Date of FDA Advisory Committee Review of ATX-101 for the Treatment of Submental Fullness
January 23, 2015

Westlake Village, Calif., January 23, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced the Dermatology and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review KYTHERA’s New Drug Application (NDA) for ATX-101 (deoxycholic acid) for improvement in the appearance of moderate to severe submental fullness in a…